APA
Piotrowska Z., Hazar-Rethinam M., Rizzo C., Nadres B., Van Seventer E. E., Shahzade H. A., Lennes I. T., Iafrate A. J., Dias-Santagata D., Leshchiner I., Jessop N. A., Hu H., Digumarthy S. R., Nagy R. J., Lanman R. B., Moody S., Niederst M. J., Engelman J. A., Hata A. N., Corcoran R. B. & Sequist L. V. (2018). Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. : JCO precision oncology.
Chicago
Piotrowska Zofia, Hazar-Rethinam Mehlika, Rizzo Coleen, Nadres Brandon, Van Seventer Emily E, Shahzade Heather A, Lennes Inga T, Iafrate Anthony J, Dias-Santagata Dora, Leshchiner Ignaty, Jessop Nicholas A, Hu Haichuan, Digumarthy Subba R, Nagy Rebecca J, Lanman Richard B, Moody Susan, Niederst Matthew J, Engelman Jeffrey A, Hata Aaron N, Corcoran Ryan B and Sequist Lecia V. 2018. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. : JCO precision oncology.
Harvard
Piotrowska Z., Hazar-Rethinam M., Rizzo C., Nadres B., Van Seventer E. E., Shahzade H. A., Lennes I. T., Iafrate A. J., Dias-Santagata D., Leshchiner I., Jessop N. A., Hu H., Digumarthy S. R., Nagy R. J., Lanman R. B., Moody S., Niederst M. J., Engelman J. A., Hata A. N., Corcoran R. B. and Sequist L. V. (2018). Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. : JCO precision oncology.
MLA
Piotrowska Zofia, Hazar-Rethinam Mehlika, Rizzo Coleen, Nadres Brandon, Van Seventer Emily E, Shahzade Heather A, Lennes Inga T, Iafrate Anthony J, Dias-Santagata Dora, Leshchiner Ignaty, Jessop Nicholas A, Hu Haichuan, Digumarthy Subba R, Nagy Rebecca J, Lanman Richard B, Moody Susan, Niederst Matthew J, Engelman Jeffrey A, Hata Aaron N, Corcoran Ryan B and Sequist Lecia V. Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. : JCO precision oncology. 2018.